Skip to main content
. 2020 Sep 2;52(9):1550–1563. doi: 10.1038/s12276-020-00493-8

Fig. 1. Methylomic features of the anti-PD-1 response in NSCLC patients.

Fig. 1

a Overview of the study design and summary of the results. b Proportion of differentially methylated promoter or enhancer regions normalized by the total number of promoters or enhancers for each chromosome.